Get the Stockscreener App
1.49
0.68%
0.01
After Hours:
1.49
Autolus Therapeutics Plc Adr stock is traded at $1.49, with a volume of 1.26M.
It is up +0.68% in the last 24 hours and up +3.47% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
See More
Previous Close:
$1.48
Open:
$1.49
24h Volume:
1.26M
Relative Volume:
0.70
Market Cap:
$396.55M
Revenue:
$75.48M
Net Income/Loss:
$-287.50M
P/E Ratio:
-1.3794
EPS:
-1.0802
Net Cash Flow:
$-311.43M
1W Performance:
+0.00%
1M Performance:
+3.47%
6M Performance:
-13.37%
1Y Performance:
+6.43%
1-Day Range:
$1.45
$1.50
1-Week Range:
$1.4485
$1.58
52-Week Range:
$1.15
$2.70
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
1.49 | 393.89M | 75.48M | -287.50M | -311.43M | -1.0802 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | H.C. Wainwright | Buy |
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround - Yahoo Finance
Apellis Pharmaceuticals (APLS) Surges 135.4%: Can This Momentum Be Sustained? - Bitget
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.50 Consensus Target Price from Analysts - Defense World
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Autolus Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - GlobeNewswire Inc.
Mak Capital One LLC Buys 9,062,518 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 - Yahoo Finance
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
What is HC Wainwright’s Estimate for AUTL FY2025 Earnings? - Defense World
Q1 Earnings Forecast for AUTL Issued By HC Wainwright - MarketBeat
What is HC Wainwright's Estimate for AUTL FY2025 Earnings? - MarketBeat
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
New Strong Sell Stocks for January 30th - Yahoo Finance
Autolus Therapeutics (NASDAQ:AUTL) Cut to Strong Sell at Zacks Research - Defense World
New Strong Sell Stocks for January 22nd - Yahoo! Finance Canada
Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket - Benzinga
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Truist Securities lowers Autolus Therapeutics stock price target on soft guidance - Investing.com
Free cash flow per share of Autolus Therapeutics Plc Sponsored ADR – FWB:6A3A - TradingView — Track All Markets
Autolus Therapeutics (NASDAQ:AUTL) Price Target Raised to $11.00 at Needham & Company LLC - Defense World
Autolus Therapeutics (NASDAQ:AUTL) Trading Up 13.5% Following Analyst Upgrade - Defense World
Autolus Therapeutics stock jumps after Needham raises price target By Investing.com - Investing.com South Africa
Autolus Therapeutics stock jumps after Needham raises price target - Investing.com
Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now? - Finviz
Perpetual Ltd Has $784,000 Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - Defense World
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
The i-80 Gold Corp (IAUX) had a good session last reading, didn’t it? - uspostnews.com
Autolus Therapeutics’ (AUTL) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Views of Wall Street’s Leading Experts on Autolus Therapeutics plc ADR - setenews.com
Wall Street analysts’ outlook for AlphaVest Acquisition Corp (ATMV) - setenews.com
Check Out Autolus Therapeutics plc ADR (AUTL)’s Trade Data Rather Than the Analysts’ Views - Setenews
Cetera Investment Advisers Has $1.41 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - Defense World
Ryan Richardson joins Autolus Therapeutics board of directors - Investing.com
An analyst sees good growth prospects for Autolus Therapeutics plc ADR (AUTL) - Setenews
Taking on analysts’ expectations and winning: EON Resources Inc (EONR) - Setenews
Ready to Jump After Recent Trade: BitMine Immersion Technologies Inc (BMNR) - Setenews
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Autolus Therapeutics plc (AUTL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Taking on analysts’ expectations and winning: enVVeno Medical Corporation (NVNO) - Setenews
Check out these key findings about Streamex Corp (STEX) - Setenews
This trade activity should not be overlooked: ETHZilla Corp (ETHZ) - Setenews
A better buy-in window may exist right now for Centessa Pharmaceuticals plc ADR (CNTA) - Setenews
How does Advanced Biomed Inc (ADVB) change from a tortoise to a hare? - Setenews
A look into Mobile health Network Solutions (MNDR)’s deeper side - Setenews
Traws Pharma Inc (TRAW) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Taking on analysts’ expectations and winning: Gelteq Ltd (GELS) - Setenews
Wall Street analysts’ outlook for Amaze Holdings Inc (AMZE) - Setenews
Is Autolus Therapeutics PLC (AUTL) One of the Fastest-Growing Penny Stocks to Buy Now? - Finviz
Autolus Therapeutics Surges: What’s Next for the Stock? - StocksToTrade
ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):